Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

PCSK9 - A Journey to Cardiovascular Outcomes.

Burnett JR, Hooper AJ.

N Engl J Med. 2018 Nov 29;379(22):2161-2162. doi: 10.1056/NEJMe1813758. No abstract available.

PMID:
30485782
2.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.

Yadav K, Sharma M, Ferdinand KC.

Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Review.

PMID:
27352986
3.

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.

Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.

Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080. Review.

PMID:
26503748
4.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

5.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
6.

Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.

Eisen A, Giugliano RP.

Curr Opin Cardiol. 2016 Nov;31(6):644-653. Review.

PMID:
27661220
7.

Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.

Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PA.

Ann Intern Med. 2016 May 3;164(9):600-7. doi: 10.7326/M15-2994. Epub 2016 Mar 22. Review.

PMID:
26999484
8.

Proprotein Convertase Subtilisin Kexin 9 Inhibitors.

Pirillo A, Catapano AL.

Cardiol Clin. 2018 May;36(2):241-256. doi: 10.1016/j.ccl.2017.12.006. Review.

9.

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.

Akin M, Skripuletz T, Napp LC, Berliner D, Akin I, Haghikia A, Akin E, Bauersachs J.

Cardiovasc Hematol Agents Med Chem. 2017;14(2):94-100. doi: 10.2174/1871525714666160727113740. Review.

PMID:
27470008
10.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.

Joseph L, Robinson JG.

Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1. Review.

PMID:
25936907
11.

[PCSK9 inhibitors reduces LDL cholesterol by 60 percent].

Nilsson P, Wiklund O.

Lakartidningen. 2017 Mar 30;114. pii: ELPY. Swedish. No abstract available.

12.

PCSK9 inhibition and the global diabetes epidemic.

Mascitelli L, Goldstein MR.

Diabetologia. 2017 Apr;60(4):751-752. doi: 10.1007/s00125-017-4217-3. Epub 2017 Jan 29. No abstract available.

PMID:
28132099
14.

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

Preiss D, Mafham M.

Diabetologia. 2017 Mar;60(3):381-389. doi: 10.1007/s00125-016-4178-y. Epub 2016 Dec 26. Review.

PMID:
28025677
15.

PCSK9 inhibitors.

Gencer B, Lambert G, Mach F.

Swiss Med Wkly. 2015 Apr 9;145:w14094. doi: 10.4414/smw.2015.14094. eCollection 2015. Review.

16.

[Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].

Christiansen MK, Jensen HK.

Ugeskr Laeger. 2015 Mar 9;177(11). pii: V11140582. Review. Danish.

PMID:
25786699
17.

PCSK9 inhibitors in the prevention of cardiovascular disease.

Latimer J, Batty JA, Neely RD, Kunadian V.

J Thromb Thrombolysis. 2016 Oct;42(3):405-19. doi: 10.1007/s11239-016-1364-1. Review. Erratum in: J Thromb Thrombolysis. 2016 Oct;42(3):420.

18.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia.

Switzer MP, Nwosu AC, Juan ZS, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2013 Dec;11(4):281-8. Review.

PMID:
24164109
19.

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.

Behr PEB, Moriguchi EH, Castro I, Bodanese LC, Dutra OP, LeĆ£es PE, Pimentel Filho P.

Arq Bras Cardiol. 2018 Jul;111(1):104-108. doi: 10.5935/abc.20180133. Review. English, Portuguese. No abstract available.

20.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.

Tice JA, Kazi DS, Pearson SD.

JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248. Review. No abstract available.

PMID:
26662572

Supplemental Content

Support Center